Leave a Message
brand logo

Premenstrual Syndrome and Premenstrual Dysphoric Disorder: Common Questions and Answers

Premenstrual syndrome is primarily diagnosed clinically, with consistent characteristic symptoms occurring in the luteal phase of the menstrual cycle and resolving during menstruation or within the week following it. For a premenstrual dysphoric disorder diagnosis, a patient’s symptoms must substantially interfere with work, school, social activities, or relationships or cause significant distress. Patients should record symptoms for at least two cycles because symptoms can vary from cycle to cycle. A symptom-tracking diary or diagnostic instrument, such as the Daily Record of Severity of Problems (a validated prospective survey tool), can be used to identify the cyclic pattern of symptoms. Selective serotonin reuptake inhibitors are first-line treatment for premenstrual syndrome and premenstrual dysphoric disorder, with rapid onset of improvement; however, adverse effects can limit their use. Cognitive behavior therapy, exercise, acupuncture or acupressure, and the herb Vitex agnus castus may be used to ameliorate premenstrual syndrome and premenstrual dysphoric disorder symptoms. Reassessment for another underlying cause of premenstrual dysphoric disorder symptoms should occur if symptoms are not controlled with medications or other interventions or persist throughout the month.

Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) manifest in a spectrum of physical and psychological symptoms that occur cyclically in the luteal phase of the menstrual cycle and resolve during menstruation or within the week following it.1 Symptoms of the two disorders include marked affective lability (mood swings), bloating, lethargy, irritability, anxiety and feelings of being out of control, appetite changes, sleep disturbances, and decreased interest in usual activities.2 Up to 90% of women of reproductive age have at least one physical or affective symptom.1,2 PMS affects approximately 20% to 30% of women, with about 2% to 5% reporting symptoms severe enough to meet the diagnostic criteria of PMDD.35 Although treatment has historically included multiple modalities, evidence-based treatment for PMS and PMDD is limited by the lack of recent, high-quality research. An approach for treatment is provided in Figure 1.

Already a member/subscriber?  Log In

Subscribe

From $165
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available
Subscribe

Issue Access

$59.95
  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available

Article Only

$34.95
  • Immediate, unlimited access to just this article
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

Continue Reading

More in AFP

More in PubMed

Copyright © 2025 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.